These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 20869448)

  • 1. Evaluation of [(11)C]MRB for assessment of occupancy of norepinephrine transporters: Studies with atomoxetine in non-human primates.
    Gallezot JD; Weinzimmer D; Nabulsi N; Lin SF; Fowles K; Sandiego C; McCarthy TJ; Maguire RP; Carson RE; Ding YS
    Neuroimage; 2011 May; 56(1):268-79. PubMed ID: 20869448
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Clinical doses of atomoxetine significantly occupy both norepinephrine and serotonin transports: Implications on treatment of depression and ADHD.
    Ding YS; Naganawa M; Gallezot JD; Nabulsi N; Lin SF; Ropchan J; Weinzimmer D; McCarthy TJ; Carson RE; Huang Y; Laruelle M
    Neuroimage; 2014 Feb; 86():164-71. PubMed ID: 23933039
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Imaging the norepinephrine transporter in humans with (S,S)-[11C]O-methyl reboxetine and PET: problems and progress.
    Logan J; Wang GJ; Telang F; Fowler JS; Alexoff D; Zabroski J; Jayne M; Hubbard B; King P; Carter P; Shea C; Xu Y; Muench L; Schlyer D; Learned-Coughlin S; Cosson V; Volkow ND; Ding YS
    Nucl Med Biol; 2007 Aug; 34(6):667-79. PubMed ID: 17707807
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Saturated norepinephrine transporter occupancy by atomoxetine relevant to clinical doses: a rhesus monkey study with (S,S)-[(18)F]FMeNER-D (2).
    Takano A; Gulyás B; Varrone A; Maguire RP; Halldin C
    Eur J Nucl Med Mol Imaging; 2009 Aug; 36(8):1308-14. PubMed ID: 19300997
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atomoxetine occupies the norepinephrine transporter in a dose-dependent fashion: a PET study in nonhuman primate brain using (S,S)-[18F]FMeNER-D2.
    Seneca N; Gulyás B; Varrone A; Schou M; Airaksinen A; Tauscher J; Vandenhende F; Kielbasa W; Farde L; Innis RB; Halldin C
    Psychopharmacology (Berl); 2006 Sep; 188(1):119-27. PubMed ID: 16896954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kinetic modeling and occupancy measures of the norepinephrine transporters in baboons using single photon emission computed tomography with (123)I-INER.
    Tavares AA; Barret O; Batis J; Alagille D; Koren A; Papin C; Kudej G; Nice K; Kordower JH; Cosgrove KP; Kloczynski T; Brenner E; Seibyl J; Tamagnan G
    Synapse; 2013 Jan; 67(1):30-41. PubMed ID: 23042643
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Decreased norepinephrine transporter availability in obesity: Positron Emission Tomography imaging with (S,S)-[(11)C]O-methylreboxetine.
    Li CS; Potenza MN; Lee DE; Planeta B; Gallezot JD; Labaree D; Henry S; Nabulsi N; Sinha R; Ding YS; Carson RE; Neumeister A
    Neuroimage; 2014 Feb; 86():306-10. PubMed ID: 24121204
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparative evaluation of positron emission tomography radiotracers for imaging the norepinephrine transporter: (S,S) and (R,R) enantiomers of reboxetine analogs ([11C]methylreboxetine, 3-Cl-[11C]methylreboxetine and [18F]fluororeboxetine), (R)-[11C]nisoxetine, [11C]oxaprotiline and [11C]lortalamine.
    Ding YS; Lin KS; Logan J; Benveniste H; Carter P
    J Neurochem; 2005 Jul; 94(2):337-51. PubMed ID: 15998285
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adult attention-deficit/hyperactivity disorder is associated with reduced norepinephrine transporter availability in right attention networks: a (S,S)-O-[
    Ulke C; Rullmann M; Huang J; Luthardt J; Becker GA; Patt M; Meyer PM; Tiepolt S; Hesse S; Sabri O; Strauß M
    Transl Psychiatry; 2019 Nov; 9(1):301. PubMed ID: 31732713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinically relevant doses of methylphenidate significantly occupy norepinephrine transporters in humans in vivo.
    Hannestad J; Gallezot JD; Planeta-Wilson B; Lin SF; Williams WA; van Dyck CH; Malison RT; Carson RE; Ding YS
    Biol Psychiatry; 2010 Nov; 68(9):854-60. PubMed ID: 20691429
    [TBL] [Abstract][Full Text] [Related]  

  • 11. PET imaging of the effects of age and cocaine on the norepinephrine transporter in the human brain using (S,S)-[(11)C]O-methylreboxetine and HRRT.
    Ding YS; Singhal T; Planeta-Wilson B; Gallezot JD; Nabulsi N; Labaree D; Ropchan J; Henry S; Williams W; Carson RE; Neumeister A; Malison RT
    Synapse; 2010 Jan; 64(1):30-8. PubMed ID: 19728366
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Synthesis and positron emission tomography evaluation of three norepinephrine transporter radioligands: [C-11]desipramine, [C-11]talopram and [C-11]talsupram.
    Schou M; Sóvágó J; Pike VW; Gulyás B; Bøgesø KP; Farde L; Halldin C
    Mol Imaging Biol; 2006; 8(1):1-8. PubMed ID: 16322935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo assessment of [11C]MRB as a prospective PET ligand for imaging the norepinephrine transporter.
    Severance AJ; Milak MS; Kumar JSD; Prabhakaran J; Majo VJ; Simpson NR; Van Heertum RL; Arango V; Mann JJ; Parsey RV
    Eur J Nucl Med Mol Imaging; 2007 May; 34(5):688-693. PubMed ID: 17180600
    [TBL] [Abstract][Full Text] [Related]  

  • 14. PET imaging of norepinephrine transporters.
    Ding YS; Lin KS; Logan J
    Curr Pharm Des; 2006; 12(30):3831-45. PubMed ID: 17073682
    [TBL] [Abstract][Full Text] [Related]  

  • 15. PET Quantification of the Norepinephrine Transporter in Human Brain with (
    Moriguchi S; Kimura Y; Ichise M; Arakawa R; Takano H; Seki C; Ikoma Y; Takahata K; Nagashima T; Yamada M; Mimura M; Suhara T
    J Nucl Med; 2017 Jul; 58(7):1140-1145. PubMed ID: 27980046
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Modeling and analysis of PET studies with norepinephrine transporter ligands: the search for a reference region.
    Logan J; Ding YS; Lin KS; Pareto D; Fowler J; Biegon A
    Nucl Med Biol; 2005 Jul; 32(5):531-42. PubMed ID: 15982584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In Vivo Evaluation of
    Zhou X; Boellaard R; Ishiwata K; Sakata M; Dierckx RAJO; de Jong JR; Nishiyama S; Ohba H; Tsukada H; de Vries EFJ; Elsinga PH
    J Nucl Med; 2017 May; 58(5):762-767. PubMed ID: 28062599
    [No Abstract]   [Full Text] [Related]  

  • 18. Occupancy of serotonin and norepinephrine transporter by milnacipran in patients with major depressive disorder: a positron emission tomography study with [(11)C]DASB and (S,S)-[(18)F]FMeNER-D(2).
    Nogami T; Takano H; Arakawa R; Ichimiya T; Fujiwara H; Kimura Y; Kodaka F; Sasaki T; Takahata K; Suzuki M; Nagashima T; Mori T; Shimada H; Fukuda H; Sekine M; Tateno A; Takahashi H; Ito H; Okubo Y; Suhara T
    Int J Neuropsychopharmacol; 2013 Jun; 16(5):937-43. PubMed ID: 23067569
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Imaging human brown adipose tissue under room temperature conditions with (11)C-MRB, a selective norepinephrine transporter PET ligand.
    Hwang JJ; Yeckel CW; Gallezot JD; Aguiar RB; Ersahin D; Gao H; Kapinos M; Nabulsi N; Huang Y; Cheng D; Carson RE; Sherwin R; Ding YS
    Metabolism; 2015 Jun; 64(6):747-55. PubMed ID: 25798999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Norepinephrine transporter availability in brown fat is reduced in obesity: a human PET study with [
    Sanchez-Rangel E; Gallezot JD; Yeckel CW; Lam W; Belfort-DeAguiar R; Chen MK; Carson RE; Sherwin R; Hwang JJ
    Int J Obes (Lond); 2020 Apr; 44(4):964-967. PubMed ID: 31636373
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.